8-K filing — Benitec Biopharma Inc. (BNTC)
Filed: 2026-09-24 AccNo: 0001193125-26-401110 Size: 163 KB Item 4.01: Changes in Registrant's Certifying Accountant Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Wedbush Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $16
Wedbush analyst Yun Zhong initiates coverage on Benitec Biopharma (NASDAQ:BNTC) with a Outperform rating and announces Price Target of $16.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Wedbush Maintains Outperform on Benitec Biopharma, Raises Price Target to $17
Wedbush analyst Yun Zhong maintains Benitec Biopharma (NASDAQ:BNTC) with a Outperform and raises the price target from $16 to $17.
Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update
Benitec Biopharma announced completion of 12-month follow-up for all six Cohort 1 patients in its BB-301 Phase 1b/2a trial for oculopharyngeal muscular dystrophy (OPMD)-related dysphagia, with clinically meaningful improvements observed. Cohort 2 is fully enrolled with three patients safely treated. The company held a Type C meeting with the FDA regarding pivotal study design and plans to initiate the pivotal trial in mid-2027. Benitec reported $180 million in cash as of June 30, 2026, with operating expenses of $51.2 million for fiscal year 2026.
Benitec Biopharma Q4 EPS $(0.26), Inline
Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.26) per share which met the analyst consensus estimate. This is a 38.1 percent increase over losses of $(0.42) per share from the same period last year.